Advances in Molecular Imaging: A market coming of age Since 2010, the market has seen stronger growth, helped by demand in...
particularly in Europe. In addition, uncertainties currently exist surrounding Mo-99 supply, the impact of theUS medical d...
neurological Disease 2oncology 2cardiovascular Disease3mi For Use In Lifesciences And The Pharmaceutical Industry 3mi Moda...
abx 33advanced Accelerator Applications 34recent Events.34mergers And Acquisitions 35products.35research & Development: An...
aby-025 Her2-binding Affibody Imaging Agent 47clinical Study Results 48alliance With Ge Healthcare49agenix 50thromboview50...
18f-av-133 67current Alliances67cardinal Health 67petnet Solutions (siemens) 67piramal Imaging 67bioscan 68pre-clinical Im...
in Vivo Optical Imaging Solutions 81current Alliances82philips 82aspect Imaging 83university Of York, Uk 83iseult Programm...
hanmi Pharmaceutical And Hyun Imc 93mjm Productos Farmaceuticos E De Radioprotecao 94philips Healthcare 94m D Anderson Can...
gammalŕc 108declipsespect 108recent Bsgi Clinical Trial Results 109current Alliances And Contracts 111surgiceye 111penrad...
pet/ct +mr Imaging Platform 124spect Systems 124spect/ct Systems 125alcyone Technology Nuclear Imaging Products 126ventri ...
piramal Imaging 152novation 152keymarker Consortium 152servicio Andaluz De Salud, Spain 152dehnel - Particle Accelerator C...
immunomedics 165leukoscan 165research And Development 165tf2 For Colorectal Cancer Imaging And Radioimmunotherapy    165pe...
ben Venue Laboratories 182premier Purchasing Partners 183cardiolite And Technelite Distribution Agreements 183australian N...
recent Key Events 193lymphoseek.194clinical Study Results 194research And Development 195expanded Indications For Lymphose...
gallimed Project - Guerbet And Cyceron 210bracco211triumf And The University Of British Columbia 211university Of Ottawa H...
mosamedix 228dupont228anticancer 228merck229stanford University 229massachusetts General Hospital 229pharmalucence 230mi P...
f-18-labelled Bombesin Analogue For Imaging Prostate Cancer 245al18f-1 For Prostate Cancer Imaging246fspg For Tumour Imagi...
inviala 260sedecal 261superargus Pre-clinical Mi Products 261seno Medical Instruments 262shimadzu 263mi Products 263pet Sy...
d-spect Cardiac Imaging System 280triad Isotopes 281ultraspect 282united Pharmacy Partners 284visualsonics (fujifilm Sonos...
Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-...
Upcoming SlideShare
Loading in...5
×

Advances in Molecular Imaging market | Researchmoz.us

262

Published on

The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
262
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Advances in Molecular Imaging market | Researchmoz.us"

  1. 1. Advances in Molecular Imaging: A market coming of age Since 2010, the market has seen stronger growth, helped by demand in under-penetrated markets, theadoption of newer-generation hybrid imaging technologies such as PET/CT and a move towards the use ofPET from SPECT, necessitating the purchase of new PET systems. The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron andthen synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, thislimits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, amajor development is the recent availability of smaller and cheaper cyclotrons which are designed to produceC-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET acceleratorexpertise. The drive towards PET has been additionally boosted by advancement in the diagnosis of Alzheimer’sdisease and the approval of Avid Radiopharmaceuticals’ Amyvid (florbetapir F-18 injection). Avid(owned by Eli Lilly) is the first company to achieve approval for a diagnostic PET tracer which estimates betaamyloid neuritic plaque density in adults with cognitive impairment. This is likely to become a busymarketplace with GE, Piramel and Navidea developing late-stage products whilst the focus of new research istargeting the tau proteins. With this report you will: Know the state of the molecular imaging market and recent advances in Alzheimer’s diagnosisEstablish the future market growth with 5-year value forecasts Know the clinical and regulatory challengesfacing the sector Assess the companies that are developing hybrid technologies Review the challenges facingproducers of radiopharmaceuticals and the research which is seeking alternative paths Know why PET isoutpacing SPECT and the advantages it brings Appreciate the regulatory hurdles affectingradiopharmaceutical producers in the US Understand the changing competitive landscape and marketpositioning of new entrants The MI market fundamentals remain solid and there are strong opportunities forgrowth within the industry. These are being driven by continued innovation and new product development,beneficial demographics, an ageing installed base of imaging equipment in the developed markets of the USand Europe, and the increasing adoption of MI technologies in emerging markets. In particular, the increasing incidence of cancer, cardiovascular and neurological diseases means that demandfor faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, willcontinue to accelerate in coming years. In addition, MI technologies will become more widely adopted asclinical evidence is established as to their benefits, and new technological innovations continue to be broughtto market, particularly related to the MI of cancer and neurological diseases such as Alzheimer’s andParkinson’s. In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies isdriving demand, where new facilities are being set up and lower-cost systems are in demand. Challenges to overcome The short and mid-term prospects for MI are to a large extent dependant on the pace of economic recovery,which will affect the ability of smaller companies to obtain financing and future healthcare budgets,Advances in Molecular Imaging: A market coming of age
  2. 2. particularly in Europe. In addition, uncertainties currently exist surrounding Mo-99 supply, the impact of theUS medical device excise tax, new regulatory hurdles for radiopharmaceuticals in the US and whether betaamyloid PET imaging (and related technologies) will be sufficiently reimbursed to facilitate their widespreaduse. A changing competitive landscape Currently, the key players in the MI market include medical diagnostic imaging equipment manufacturerssuch as Philips, Siemens and GE; radiopharmaceutical and imaging agent companies such as GE, Bracco,Covidien, IBA Molecular and Lantheus Medical Imaging; and companies that operate radiopharmacies suchas Cardinal Health, Triad Isotopes and Siemens. The landscape is shifting and, despite pharmaceuticalcompanies such as BMS and Bayer leaving the MI market, others have been keen to enter. Piramal Group has gained a strong position in MI. The company now owns the intellectual property anddevelopment, marketing and distribution rights for Bayers lead compound, florbetaben, which is seen as apromised imaging agent for AD. Through the Bayer transaction, Piramal now also owns other clinical andpre-clinical agents that are in development for cardiology and oncology imaging. Progenics Pharmaceuticals is focusing on developing therapeutic radiopharmaceuticals and targeted MIagents for oncology, through its acquisition of Molecular Insight Pharmaceuticals. And it is not just Pharma companies: PerkinElmer has acquired VisEn Medical and Caliper Lifesciences, who’s in vivo and in vitrodiagnostics are used in pre-clinical drug development work. Samsung has strengthened its medical imagingbusiness with the acquisition, in January 2013, of NeuroLogica. Although mainly focused on portable CTscanners, NeuroLogica also offers the inSPira HD portable SPECT system. The report covers companies active in the major MI sectors Nuclear Imaging Near infrared or optical imaging Ultrasound MRI MRI/PET MRI/SPECT Tracers andRadiopharmaceuticals This report answers key business questions. What alternatives are being considered to mitigate the ongoing supply issues with the Molybdenum-99isotope? In which therapy sectors are MI technologies playing a key diagnostic role and with what success?What collaborative role are academic institutions playing in MI development? Which companies are mostadvanced in introducing hybrid imaging systems? For which tracing agent did Navidea receive FDA approvalin March 2013? Which 2 Spanish companies did Advanced Accelerator Applications acquire in January 2013?What development in 2012 strengthened Bruker’s position in the pre-clinical imaging sector? Whatdevelopments are helping GE maintain its leading position in the molecular imaging sector?table Of Contentsexecutive Summary 1introduction 1applications Of Mi.2Advances in Molecular Imaging: A market coming of age
  3. 3. neurological Disease 2oncology 2cardiovascular Disease3mi For Use In Lifesciences And The Pharmaceutical Industry 3mi Modalities 4hybrid Mri/pet Imaging 5hybrid Mri/spect Imaging 7tracers And Radiopharmaceuticals 7competitive Landscape 8new Market Entrants9market Consolidation 10collaborative Development Efforts 11barriers To Market Entry And Challenges For Smaller Companies 12current Market Dynamics 13nuclear Imaging Adoption 13market Insight 13fig.1: Diagnostic Imaging Systems Market By Modality, 2012 14fig.2: Medical Imaging Market, 2005-2012 (us$ Billion)* 15fig.3: Nuclear Imaging Equipment Market, 2007-2012 (us$ Billion)* 16fig.4: Molecular Imaging Market By End-use Product Type, 201016molybdenum-99 Isotope Supply Issues16recent Developments In The Pet Market 21alzheimer’s Disease Pet Imaging 22lymphoseek Lymph Node Imaging 26pet Regulatory Approval Issues 26improved Optical Imaging Techniques 27market Outlook 8molecular Imaging: Market Drivers, Restraints & Future Opportunities 28fig.5: Nuclear Imaging Equipment Market, 2012-2017e (us$ Million)* 29fig.6: Pre-clinical Imaging Systems Market, 2012-2017e (us$ Million) 29fig.7: Radiopharmaceuticals Market, 2012-2017e (us$ Million) 30fig.8: Molecular Imaging End-use Products Market, 2012-2017e (us$ Million)* 30molecular Imaging Companies 31abt Molecular Imaging31“dose On Demand” Biomarker Generator31Advances in Molecular Imaging: A market coming of age
  4. 4. abx 33advanced Accelerator Applications 34recent Events.34mergers And Acquisitions 35products.35research & Development: Annexin V-128.36current Alliances36uwrc Społka Z Ograniczoną Odpowiedzialnością, University Of Warsaw 36ge Healthcare 37institut Curie 37iason Gmbh 37european Molecular Imaging Manufacturers Association 37bracco 37financial Performance 37advanced Cyclotron Systems 38recent Events38products.38tr 24 Cyclotrons 38tr 30 Cyclotrons 39tr Pet Cyclotrons39cyclotec R&d Programme 39current Alliances 40triumf 40ge Healthcare 41advanced Medical Isotope 42products In Development 42us Production Of Molybdenum-99 43alliance With Gsg International 44financial Performance 44amic - Operating Results, 2007-2011 (us$ Thousand) 45fig.9: Amic - Revenue By Type, 2011.45latest Results 45affibody 47Advances in Molecular Imaging: A market coming of age
  5. 5. aby-025 Her2-binding Affibody Imaging Agent 47clinical Study Results 48alliance With Ge Healthcare49agenix 50thromboview50pulmonary Embolism Application 50deep Vein Thrombosis 51alseres Pharmaceuticals 52altropane 52clinical Study Results 52navidea Biopharmaceuticals Licence Agreement.53anticancer. 54current Alliances54uvp 54caliper Life Sciences (perkinelmer).55indec Systems55olympus.55aposense 56[18f]-ml-10 And Earlitest56clinical Trial Results57current Agreements57iba 57sigma-aldrich 58art Advanced Research Technologies 59art: Recent Events.59products.59optix Mx3 60softscan Optical Breast Imaging System 60fenestra Contrast Agents 61astellas Pharma 62lexiscan (regadenoson) 62clinical Trial Results 63adenoscan (adenosine Injection)63cardiac Imaging Revenue 64fig.10: Astellas Pharma’s Cardiac Imaging Sales, Fiscal 2008-2011 (us$ Million) 64avid Radiopharmaceuticals (eli Lilly) 65amyvid (florbetapir F 18 Injection) 65clinical Study Results 66products In Development 67Advances in Molecular Imaging: A market coming of age
  6. 6. 18f-av-133 67current Alliances67cardinal Health 67petnet Solutions (siemens) 67piramal Imaging 67bioscan 68pre-clinical Imaging Products.68bioflect 68nanospect/ct And Nanopet/ct 69hispect 70imappi Consortium 70biospace Lab 71recent Key Events 71products.71photon Imager Systems 71beta Imager 72current Alliances72centre For Advanced Biomedical Imaging At University College London 72imabio Group 73bracco 74products.74cardiogen-82 74research And Development75ultrasound Mi Contrast Agents 76current Alliances76rete Ventures 76nordion 76advanced Accelerator Applications (aaa).76imarx Therapeutics 77visualsonics 77bruker 78recent Key Events 78products.79pre-clinical Mri 79albira Pet/spect/ct System 81Advances in Molecular Imaging: A market coming of age
  7. 7. in Vivo Optical Imaging Solutions 81current Alliances82philips 82aspect Imaging 83university Of York, Uk 83iseult Programme 83siemens 84bv Cyclotron Vu 85products 85current Alliances85iba Group 85alliance With Vu University Medical Centre 85cardinal Health 86recent Key Events 86imaging Facilities 86products 87cardiac Imaging Agents 87current Alliances And Collaborations 88lantheus Medical Imaging 88eli Lilly 88provision Healthcare 88university Of Washington 88american College Of Radiology Imaging Network 88ohio Third Frontier And Ohio State University 89eckert & Ziegler 89ge Healthcare 89navidea Biopharmaceuticals 90cellpoint 91recent Key Events 91ec Technology9199mtc-ec-g For Oncology 9299mtc-ec-g For Cardiology 9299mtc-ec-metronidazole For Stroke And Tumour Hypoxia 92n4 Technology 93dual Agent Technology 93beta Cell Technology 93current Alliances93Advances in Molecular Imaging: A market coming of age
  8. 8. hanmi Pharmaceutical And Hyun Imc 93mjm Productos Farmaceuticos E De Radioprotecao 94philips Healthcare 94m D Anderson Cancer Center 94covidien (mallinckrodt) 95recent Key Events 95mallinckrodt Plc95products.96radiopharmaceuticals 96current Alliances97rapidscan Pharma Solutions 97positron 98institute Of Atomic Energy, Poland 98financial Performance 98fig.11: Covidien’s Imaging Sales, 2006-2012 (us$ Million) 99mallinckrodt In Fiscal 2012 99mallinckrodt Plc - Revenue By Division, 2010-2012 (us$ Million) 99fig.12: Mallinckrodt Plc - Revenue By Division, 2012.100mallinckrodt Global Medical Imaging - Revenue By Geographic Region, 2010-2012 (us$ Million) 100fig.13: Mallinckrodt Global Medical Imaging - Revenue By Geographic Region, 2012100mallinckrodt Global Medical Imaging - Revenue By Key Product, 2010-2012 (us$ Million) 101fig.14: Mallinckrodt Global Medical Imaging - Revenue By Key Product, 2012 101latest Results 101cyclopharma 102digirad 103recent Key Events103products 103ergo 103cardius Xpo Series 104alliance With Dilon Diagnostics105financial Performance 105digirad - Operating Results, 2008-2012 (us$ Million) 105fig.15: Digirad - Revenue By Division, 2012 106dilon Diagnostics 107recent Key Events107dilon 6800 Gamma Camera 107dilon 6800 Acella 108Advances in Molecular Imaging: A market coming of age
  9. 9. gammalŕc 108declipsespect 108recent Bsgi Clinical Trial Results 109current Alliances And Contracts 111surgiceye 111penrad 111digirad 111terason Ultrasound 111eckert & Ziegler 112recent Key Events.112products And Services 113isotope Products 113radiopharma Products.113contracts And Alliances.114euromedic International 114zag Zyklotron 114polish Medical University Of Gdansk.114cardinal Health 114financial Performance 114eczacibasi-monrol Nuclear Products 115mergers And Acquisitions 115erigal 116fluoropharma Medical 117product Pipeline 117cardiopet 117bfpet.118vasopet 118azpet 118gamma Medica-ideas 119lumagem Molecular Breast Imaging System 119clinical Study Results 120pre-clinical Imaging 121ge Healthcare 123recent Key Events 123products 124Advances in Molecular Imaging: A market coming of age
  10. 10. pet/ct +mr Imaging Platform 124spect Systems 124spect/ct Systems 125alcyone Technology Nuclear Imaging Products 126ventri Nuclear Cardiology System 127pet/ct 127pet Radiopharmacy Products 129nuclear And Molecular Imaging Agents 130research And Development 132research Projects 133research Collaborations 137distribution And Other Agreements 141advanced Accelerator Applications (aaa) 141rapidscan Pharma Solutions 141nihon Medi-physics Joint Venture With Sumitomo Chemical 141lantheus Medical Imaging 142financial Performance 142ge Healthcare Operating Results, 2007-2012 (us$ Million) 142fig.16: Ge Healthcare - Revenue By Product Area, 2011* 142guerbet 143 research And Development 143 current Alliances And Collaborations.143 gallimed Project - Nordion And Cyceron 143 imakinib 144 iseult Programme 144 other Projects 145hamamatsu Photonics 146products 146animal Pet Scanner Shr-7700 146research And Development 146reflectance Diffuse Optical Tomography 146iba Group 148recent Key Events149mi Products And Services 149iba Molecular - Radiopharmaceuticals 149iba Radiopharma Solutions 150research And Development 151current Alliances And Contracts152Advances in Molecular Imaging: A market coming of age
  11. 11. piramal Imaging 152novation 152keymarker Consortium 152servicio Andaluz De Salud, Spain 152dehnel - Particle Accelerator Components And Engineering 153cea, France, And Ire, Belgium 153bio Molecular Industries 153aposense 153bv Cyclotron Vu 153hae Dong Co Ltd 154lantheus Medical Imaging 154wilex 154financial Performance 155imaginab 156recent Key Events 156grants And Financing 157research Projects 157current Alliances And Contracts158oxford Biomedica 158h Lundbeck 158macrogenics 158singapore Radiopharmaceuticals 159bzl Biologics 159ge Imanet 160keymarker Consortium 160university Of California, Los Angeles 160dainippon Seiki 160eurogentec 161singapore’s Agency For Science, Technology And Research 161glaxosmithkline161imaging Diagnostic Systems 162ctlm System162fda Approval Application 162fluorescence And Molecular Imaging 163laser Imager For Lab Animals (lila) 163financial Performance 164idsi - Operating Results, 2008-2012 (us$) 164latest Results 164Advances in Molecular Imaging: A market coming of age
  12. 12. immunomedics 165leukoscan 165research And Development 165tf2 For Colorectal Cancer Imaging And Radioimmunotherapy 165peptides For Imaging 166indec Systems 169intramedical Imaging 170jazz Pharmaceuticals 171prostascint 171clinical Study Results 172jubilant Draximage 173products 173ruby-fill Sr-82/rb-82 Generator And Rubidium Elution System 174draximage Sestamibi.174research And Development 174current Alliances 174positron174lantheus Medical Imaging 176recent Key Events 176products 177technelite (technetium Tc99m Generator) And Leu Technelite 177ablavar (gadofosveset Trisodium) 177cardiolite 178neurolite 179definity, Neurolite And Cardiolite Supply Issues179research And Development 180flurpiridaz F 18 180lmi 1195 For Cardiac Pet Imaging 180bms 753951 181current Alliances And Contracts181institute For Radioelements, Belgium 181fujifilm Ri Pharma 182nordion 182ntp Radioisotopes 182jubilant Hollisterstier 182Advances in Molecular Imaging: A market coming of age
  13. 13. ben Venue Laboratories 182premier Purchasing Partners 183cardiolite And Technelite Distribution Agreements 183australian Nuclear Science And Technology Organisation 183iba Group 183financial Performance 184lantheus Medical Imaging - Operating Results, 2007-2011 (us$ Million)184lantheus Medical Imaging - Sales By Key Product Line, 2008-2011 (us$ Million) 184fig.17: Lantheus Medical Imaging - Revenue By Product Line, 2011 185latest Results 185lightools Research 186mi Products 186pan-a-see-ya Panorama 186macro-illumination Imaging System 186macro-imaging System Plus 186mediso Medical Imaging Systems 187recent Key Events187nanoscan Pre-clinical Imaging.187nanoscan Spect/mri 187nanoscan Pm Pet/mri 188clinical Imaging 188anyscan Spect-ct-pet 188nucline Gamma Cameras 189current Alliances And Collaborations.189spadnet 189insert 190absolute Imaging Solutions 190aspect Imaging 190milabs 191products 191vector 191quick-start Spect (u-spectqs)191u-spect-ii/ct191u-spect Scanners191current Alliances 192mid-atlantic Imaging Services 192navidea Biopharmaceuticals 193Advances in Molecular Imaging: A market coming of age
  14. 14. recent Key Events 193lymphoseek.194clinical Study Results 194research And Development 195expanded Indications For Lymphoseek 195rigscan 196nav5001 [123i]-e-iacft Injection (altropane) 197nav4694 198current Alliances And Licences 199alseres Pharmaceuticals 199astrazeneca 199dow Chemical Company 200laureate Pharma.200cardinal Health.200university Of California, San Diego 200naviscan 201recent Key Events201positron Emission Mammography Scanner 201pem Clinical Study Results 202stereo Navigator 203mimviewer Pem 204current Alliances 204ledford Medical Electronics204chindex Medical 204tecnologie Avanzate 204nuclear Medicine Distributors 204sceti 204hae Dong Co Ltd 205mimvista 205neurologica (samsung Electronics) 206nordion 207 recent Key Events208 products 208 medical Isotopes.208 current Alliances 210 the Open Joint Stock Company “isotope” And Research Institute Of Atomic Reactors, Russia210 lantheus Medical Imaging 210Advances in Molecular Imaging: A market coming of age
  15. 15. gallimed Project - Guerbet And Cyceron 210bracco211triumf And The University Of British Columbia 211university Of Ottawa Heart Institute 211financial Performance 212nordion - Results From Continuing Operations, 2010-2012 (us$ Million) 212fig.18: Nordion - Percentage Of Revenue By Segment, 2012 213nordion - Sales And Earning By Segment, 2010-2012 (us$ Million) 213medical Isotope Segment Results.213nordion - Medical Isotope Sales By Product Line, 2010-2012 (us$ Million) 214fig.19: Nordion - Percentage Of Medical Isotope Revenue By Product Line, 2012 214latest Results And 2013 Outlook 214novelos Therapeutics 216124i-clr1404 (light) 216clr1502 (glow2) 217nuview Life Sciences 218alliance With Thomas Jefferson University 218vpac1 For Imaging Prostate Cancer 218nls-vpac For Imaging Breast Cancer 219nls-vpac1 Labelled With Ga-68 219nvls/fxa-18 For Cardiovascular Disease 219oncovision 220 albira Pet/spect/ct System 220 mammi Breast Pet Imaging System 220perkinelmer 221recent Key Events222fluorescence Molecular Tomography Imaging Systems 222multispecies Imaging Module.223imaging Agents 223her2sense 225caliper Life Sciences’ Pre-clinical Imaging Systems 226ivis Imaging Systems 226quantum Fx Microct System 226living Image Multi Modality Software Module And The Mouse Imaging Shuttle 227maestro Mi Systems 227current Alliances 228Advances in Molecular Imaging: A market coming of age
  16. 16. mosamedix 228dupont228anticancer 228merck229stanford University 229massachusetts General Hospital 229pharmalucence 230mi Products 230sulfur Colloid Injection.230philips Healthcare 232recent Key Events232nuclear Medicine Products 232ingenuity Tf Pet/mr 233pet/ct 233spect/ct Systems 235brightview Spect 235nuclear Gamma Cameras 235intellispace Portal 236extended Brilliance Workspace 236pre-clinical Imaging 236imalytics Workspace236research And Development 237high Tech Campus 237molecular Imaging R&d Projects 237research Alliances 240distribution And Licensing Agreements.241rosatom 241bioscan 241sun Microsystems 241financial Performance 242philips Healthcare: Operating Results, 2008-2012 (eur Million) 242fig.20: Philips Healthcare - Revenue By Segment, 2012 243fig.21: Philips Healthcare - Revenue By Region, 2012 243piramal Enterprises 244research And Development 244florbetaben Pet Tracer244ga68-bombesin For Prostate Cancer Pet Imaging 245Advances in Molecular Imaging: A market coming of age
  17. 17. f-18-labelled Bombesin Analogue For Imaging Prostate Cancer 245al18f-1 For Prostate Cancer Imaging246fspg For Tumour Imaging.246l-5-f-18-ethoxy-tryptophan For Tumour-specific Imaging 247current Alliances 248ion Bean Applications 248positron 249recent Key Events250products And Services 250pet Products250posirx Radiopharmaceutical System 251tech-assist 251current Alliances And Contracts252jubilant Draximage 252institute Of Nuclear Research, Troitsk, Russia 252amerinet 252arronax Cyclotron Facility, France 252covidien 252financial Performance 253positron - Operating Results, 2007-2011 (us$ Thousand) 253latest Results 253progenics Pharmaceuticals 254 recent Key Events254 research And Development 254 99mtc-mip-1404 255proportional Technologies 257cu-62 Micro-generator 257products In Development 257pet Camera For Breast Imaging 258pet Camera For Small Animal Studies 258scintomics 259products 259hotbox-iii (hb-iii) 259gallelut 259grp Modules 259μ-icr 259Advances in Molecular Imaging: A market coming of age
  18. 18. inviala 260sedecal 261superargus Pre-clinical Mi Products 261seno Medical Instruments 262shimadzu 263mi Products 263pet Systems 263pet/ct Systems 263clairvivo Pre-clinical Pet System 263research Agreement With The National Cancer Center, Tokyo, Japan 264siemens Healthcare 265recent Key Events265molecular Imaging And Pet Products 265biograph Mmr Mri-pet System 266pet/ct 266spect And Spect/ct Systems 268mi Workstations And Software 269pre-clinical Imaging 270biomarkers 271r&d Activities 273siemens Molecular Imaging Biomarker Research 273research Agreements 275supply, Distribution And Licensing Agreements 276avid Radiopharmaceuticals (eli Lilly) 276cleveland Clinic 277financial Performance 277fig.22: Siemens Healthcare: Sales By Location Of Customer, 2012 277latest Results 277sofie Biosciences 278genisys4 27818f-fac Probes 279elixys 279spectrum Dynamics 280Advances in Molecular Imaging: A market coming of age
  19. 19. d-spect Cardiac Imaging System 280triad Isotopes 281ultraspect 282united Pharmacy Partners 284visualsonics (fujifilm Sonosite) 285recent Key Events285products 285vevo Lazr Photoacoustic Imaging System 285vevo 2100.286vevo 770 286micromarker Contrast Agent Kits 287current Alliances 287seno Medical Instruments 287bracco 287university Of Virginia 287wilex 288redectane 288alliance With Iba Group 289appendices 290appendix 1 - List Of Abbreviations Table Of Contentsappendix 2 - Report Methodology 291290appendix 2 - Report Methodology 291About Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Advances in Molecular Imaging: A market coming of age
  20. 20. Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Advances in Molecular Imaging: A market coming of age

×